Pressmaster / Shuterstock.com
5 May 2016Americas
AstraZeneca completes acquisition of Takeda’s respiratory business
AstraZeneca has completed its acquisition of pharmaceutical company Takeda’s respiratory business.
The deal, which was first announced in December last year, was completed today, May 5, AstraZeneca said in a statement.
The agreement covers the rights to the Daliresp (roflumilast) drug which is used in the treatment of chronic obstructive pulmonary disease.
Under the terms of the agreement, AstraZeneca will make a payment of $575 million to Takeda.
Editor's picks
Editor's picks
Biotechnology
30 January 2024
Americas
5 May 2016 Pharmaceutical company Allergan has received approval from the US Food and Drug Administration to launch a generic version of a cholesterol drug owned by AstraZeneca.
Americas
6 May 2016 The US Federal Trade Commission has approved a final order settling charges that pharmaceutical company Hikma’s buyout of Roxane Laboratories and Boehringer Ingelheim Roxane would be anticompetitive.
Big Pharma
18 March 2021 Genevant Sciences has entered into a licence agreement for Takeda to develop and market a new liver fibrosis treatment.
Americas
5 May 2016 Pharmaceutical company Allergan has received approval from the US Food and Drug Administration to launch a generic version of a cholesterol drug owned by AstraZeneca.
Americas
6 May 2016 The US Federal Trade Commission has approved a final order settling charges that pharmaceutical company Hikma’s buyout of Roxane Laboratories and Boehringer Ingelheim Roxane would be anticompetitive.
Big Pharma
18 March 2021 Genevant Sciences has entered into a licence agreement for Takeda to develop and market a new liver fibrosis treatment.